In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Loxo Oncology (NASDAQ: LOXO), with a price target of $215. The company’s shares closed on Friday at $186.69, close to its 52-week high of $187.38.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 15.4% and a 66.1% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Sarepta Therapeutics.
Currently, the analyst consensus on Loxo Oncology is Strong Buy and the average price target is $218.67, representing a 17.1% upside.
In a report issued on May 30, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $200 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $187.38 and a one-year low of $67.02. Currently, Loxo Oncology has an average volume of 450.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT.
